Hyundai Pharmaceutical Co., Ltd. (004310.KS)
KRW 3710.0
(-2.62%)
KRW 3710.0
(-2.62%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 68.31 Billion KRW | 184.25% |
| 2022 | 60.86 Billion KRW | 5.15% |
| 2021 | 57.88 Billion KRW | 4.73% |
| 2020 | 55.26 Billion KRW | -10.34% |
| 2019 | 61.64 Billion KRW | -2.35% |
| 2018 | 63.12 Billion KRW | 5.26% |
| 2017 | 59.97 Billion KRW | 33.84% |
| 2016 | 44.8 Billion KRW | 10.44% |
| 2015 | 40.57 Billion KRW | 3.3% |
| 2014 | 39.27 Billion KRW | 1.95% |
| 2013 | 38.52 Billion KRW | -11.62% |
| 2012 | 43.58 Billion KRW | 1.29% |
| 2011 | 43.03 Billion KRW | -7.96% |
| 2010 | 46.75 Billion KRW | -3.24% |
| 2009 | 48.32 Billion KRW | -1.7% |
| 2008 | 49.15 Billion KRW | 1.29% |
| 2007 | 48.52 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 17.12 Billion KRW | 3.24% |
| 2024 Q3 | 19.86 Billion KRW | 15.97% |
| 2024 Q1 | 16.58 Billion KRW | -63.93% |
| 2023 Q3 | 16.75 Billion KRW | -11.8% |
| 2023 Q2 | 18.99 Billion KRW | 28.91% |
| 2023 Q1 | 14.73 Billion KRW | -13.34% |
| 2023 Q4 | 45.98 Billion KRW | 174.39% |
| 2023 FY | 173.01 Billion KRW | 184.25% |
| 2022 Q3 | 14.85 Billion KRW | -2.78% |
| 2022 FY | 60.86 Billion KRW | 5.15% |
| 2022 Q4 | 17 Billion KRW | 14.47% |
| 2022 Q2 | 15.28 Billion KRW | 11.33% |
| 2022 Q1 | 13.72 Billion KRW | -15.87% |
| 2021 Q2 | 15.06 Billion KRW | 15.96% |
| 2021 Q3 | 13.51 Billion KRW | -10.28% |
| 2021 Q1 | 12.99 Billion KRW | -14.0% |
| 2021 FY | 57.88 Billion KRW | 4.73% |
| 2021 Q4 | 16.31 Billion KRW | 20.71% |
| 2020 Q1 | 14.66 Billion KRW | 1.3% |
| 2020 Q4 | 15.1 Billion KRW | 7.23% |
| 2020 Q2 | 11.41 Billion KRW | -22.21% |
| 2020 Q3 | 14.08 Billion KRW | 23.47% |
| 2020 FY | 55.26 Billion KRW | -10.34% |
| 2019 Q3 | 15.69 Billion KRW | -3.55% |
| 2019 FY | 61.64 Billion KRW | -2.35% |
| 2019 Q2 | 16.27 Billion KRW | 7.19% |
| 2019 Q4 | 14.48 Billion KRW | -7.76% |
| 2019 Q1 | 15.18 Billion KRW | -9.88% |
| 2018 Q1 | 15.41 Billion KRW | -36.84% |
| 2018 Q2 | 15.99 Billion KRW | 3.76% |
| 2018 Q3 | 14.86 Billion KRW | -7.1% |
| 2018 FY | 63.12 Billion KRW | 5.26% |
| 2018 Q4 | 16.85 Billion KRW | 13.39% |
| 2017 FY | 59.97 Billion KRW | 33.84% |
| 2017 Q4 | 24.41 Billion KRW | 97.45% |
| 2017 Q3 | 12.36 Billion KRW | -0.09% |
| 2017 Q2 | 12.37 Billion KRW | 14.31% |
| 2017 Q1 | 10.82 Billion KRW | -7.6% |
| 2016 Q1 | 10.13 Billion KRW | -6.85% |
| 2016 Q2 | 12.85 Billion KRW | 26.84% |
| 2016 Q4 | 11.71 Billion KRW | 16.02% |
| 2016 Q3 | 10.09 Billion KRW | -21.47% |
| 2016 FY | 44.8 Billion KRW | 10.44% |
| 2015 Q1 | 9.56 Billion KRW | 0.45% |
| 2015 FY | 40.57 Billion KRW | 3.3% |
| 2015 Q4 | 10.88 Billion KRW | 14.69% |
| 2015 Q3 | 9.48 Billion KRW | -10.75% |
| 2015 Q2 | 10.63 Billion KRW | 11.11% |
| 2014 Q2 | 10.32 Billion KRW | 10.77% |
| 2014 Q1 | 9.32 Billion KRW | -0.04% |
| 2014 Q4 | 9.52 Billion KRW | -5.78% |
| 2014 FY | 39.27 Billion KRW | 1.95% |
| 2014 Q3 | 10.1 Billion KRW | -2.12% |
| 2013 Q1 | 9.08 Billion KRW | -16.01% |
| 2013 Q2 | 10.13 Billion KRW | 11.49% |
| 2013 Q3 | 9.97 Billion KRW | -1.49% |
| 2013 Q4 | 9.32 Billion KRW | -6.52% |
| 2013 FY | 38.52 Billion KRW | -11.62% |
| 2012 Q3 | 10.7 Billion KRW | -10.13% |
| 2012 FY | 43.58 Billion KRW | 1.29% |
| 2012 Q1 | 10.39 Billion KRW | 6.54% |
| 2012 Q2 | 11.9 Billion KRW | 14.59% |
| 2012 Q4 | 10.81 Billion KRW | 1.1% |
| 2011 FY | 43.03 Billion KRW | -7.96% |
| 2011 Q1 | 10.37 Billion KRW | -0.02% |
| 2011 Q2 | 11.32 Billion KRW | 9.15% |
| 2011 Q3 | 11.58 Billion KRW | 2.36% |
| 2011 Q4 | 9.75 Billion KRW | -15.83% |
| 2010 Q3 | 12.85 Billion KRW | 3.47% |
| 2010 Q1 | 11.1 Billion KRW | 2.53% |
| 2010 Q4 | 10.37 Billion KRW | -19.31% |
| 2010 FY | 46.75 Billion KRW | -3.24% |
| 2010 Q2 | 12.42 Billion KRW | 11.91% |
| 2009 FY | 48.32 Billion KRW | -1.7% |
| 2009 Q4 | 10.82 Billion KRW | -22.8% |
| 2009 Q3 | 14.02 Billion KRW | 7.84% |
| 2009 Q2 | 13 Billion KRW | 24.2% |
| 2009 Q1 | 10.47 Billion KRW | -16.63% |
| 2008 Q3 | 12.18 Billion KRW | -6.58% |
| 2008 Q4 | 12.56 Billion KRW | 3.06% |
| 2008 Q2 | 13.04 Billion KRW | 14.67% |
| 2008 Q1 | 11.37 Billion KRW | -8.71% |
| 2008 FY | 49.15 Billion KRW | 1.29% |
| 2007 Q2 | 12.21 Billion KRW | 17.7% |
| 2007 FY | 48.52 Billion KRW | 0.0% |
| 2007 Q3 | 13.46 Billion KRW | 10.23% |
| 2007 Q4 | 12.46 Billion KRW | -7.45% |
| 2007 Q1 | 10.38 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -44.562% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 77.076% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | 75.466% |
| HANDOK Inc. | 153.76 Billion KRW | 55.575% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | 1.304% |
| Yuhan Corporation | 489.94 Billion KRW | 86.057% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 77.746% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -63.465% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 88.819% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | 5.102% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 60.774% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -70.551% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | 26.98% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | 40.457% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -44.562% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -60.839% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | 8.978% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -16.484% |
| JW Holdings Corporation | 301.25 Billion KRW | 77.325% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | 73.823% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 83.284% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 71.407% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 46.494% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | -3.893% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | 60.949% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -44.562% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | 72.579% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 87.811% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 71.407% |
| Yuhan Corporation | 489.94 Billion KRW | 86.057% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | 64.727% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | 1.666% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -21.914% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 71.407% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | 45.953% |
| Korea United Pharm Inc. | 118.21 Billion KRW | 42.214% |
| CKD Bio Corp. | 25.19 Billion KRW | -171.121% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | 69.229% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | 58.628% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | -2.851% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 46.494% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 80.522% |
| Boryung Corporation | 285.16 Billion KRW | 76.045% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | 21.968% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 60.774% |
| JW Lifescience Corporation | 20.26 Billion KRW | -237.146% |